Hi all, I have a couple of questions but I appreciate responses with support of reported info not views, or at least views with supportive reason/evidence. Thanks.
1- Reflecting on SI's comments re link between ph 3 and current product; Does it mean FDA's concern centred on whether the product made/used for phase 3 trial was the same as the current commercially risk product? Is there, or how can we deduct an evidence of FDA's position on this (even from the CC)?
2- SI: "We also proposed providing FDA with new clinical trial data in adults, ..." Does this mean we will provided the with new-to-FDA data, i.e., data that has been gathered since what was presented to FDA (perhaps as part of BLA resubmission and/or well before the complete response?). Or is SI talking bout new data to be gathered with new trial (going by how he talks about cost reduction for funding)?
- Forums
- ASX - By Stock
- MSB
- Mesoblast CC Transcript 31/8
Mesoblast CC Transcript 31/8, page-50
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.39 |
Change
-0.005(0.36%) |
Mkt cap ! $1.581B |
Open | High | Low | Value | Volume |
$1.40 | $1.42 | $1.38 | $4.391M | 3.156M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 48253 | $1.39 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.40 | 32922 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 48253 | 1.385 |
6 | 90251 | 1.380 |
15 | 100605 | 1.375 |
8 | 96825 | 1.370 |
3 | 43018 | 1.365 |
Price($) | Vol. | No. |
---|---|---|
1.395 | 32922 | 2 |
1.400 | 107386 | 11 |
1.405 | 24018 | 1 |
1.410 | 116617 | 7 |
1.415 | 58649 | 2 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
EL8
ELEVATE URANIUM LTD
Murray Hill, MD & CEO
Murray Hill
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online